Outlines of the biochemistry of osteoarthritis

Current Rheumatology Reviews

Volumn 6, Issue 4, 2010, Pages 234-250

  Livshits, Gregory ^a   Ermakov, Sergey ^a   Vilker, Arthur ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Adipokines; Articular cartilage; Inflammation; Mineralization; Subchondral bone; Synovitis

Indexed keywords

AGGRECAN; BONE SIALOPROTEIN; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CELECOXIB; COLLAGEN TYPE 2; HUMAN GLYCOPROTEIN OF CARTILAGE 39; HYALURONIC ACID; PROTEINASE; SECRETORY PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; ARTICULAR CARTILAGE; BIOCHEMISTRY; CALCIFICATION; CARTILAGE FRACTURE; EXTRACELLULAR MATRIX; HUMAN; OBESITY; OSTEOARTHRITIS; PRIORITY JOURNAL; SYNOVITIS;

EID: 78649370573     PISSN: 15733971     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339710793205684     Document Type: Article

References (162)

1. Arden N, Nevitt MC. Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol 2006; 20(1): 3-25.
2. Goldring MB, Otero M, Tsuchimochi K, Ijiri K, Li Y. Defining the roles of inflammatory and anabolic cytokines in cartilage metabolism. Ann Rheum Dis 2008; 67(Suppl 3): iii75-82.
3. Attur M, Samuels J, Krasnokutsky S, Abramson SB. Targeting the synovial tissue for treating osteoarthritis (OA): where is the evidence? Best Pract Res Clin Rheumatol 2010; 24(1): 71-9.
4. Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Rheum Dis Clin North Am 2008; 34(3): 515-29.
5. Valdes AM, Spector TD. The contribution of genes to osteoarthritis. Med Clin North Am 2009; 93(1): 45-66.
6. Dai J, Ikegawa S. Recent advances in association studies of osteoarthritis susceptibility genes. J Hum Genet 2010; 55(2): 77-80.
7. Valdes AM, Spector TD. The genetic epidemiology of osteoarthritis. Curr Opin Rheumatol 2010; 22(2): 139-43.
8. MacGregor AJ, Li Q, Spector TD, Williams FM. The genetic influence on radiographic osteoarthritis is site specific at the hand, hip and knee. Rheumatology (Oxford) 2009; 48(3): 277-80.
9. Garstang SV, Sittik TP. Osteoarthritis: epidemiology, risk factors, and path physiology. Am J Phys Med Rehabil 2006; 85(11 Suppl): S2-S11.
10. Rollín R, Marco F, Jover JA, et al. Early lymphocyte activation in the synovial microenvironment in patients with osteoarthritis: comparison with rheumatoid arthritis patients and healthy controls. Rheumatol Int 2008; 28(8): 757-64.
11. Christensen R, Bartels EM, Astrup A, Bliddal H. Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis. Ann Rheum Dis 2007; 66(4): 433-9.
12. Livshits G, Zhai G, Hart DJ, et al. Interleukin-6 is a significant predictor of radiographic knee osteoarthritis: The Chingford Study. Arthritis Rheum 2009; 60(7): 2037-45.
13. Sowers M, Karvonen-Gutierrez CA, Palmieri-Smith R, Jacobson JA, Jiang Y, Ashton-Miller JA. Knee osteoarthritis in obese women with cardiometabolic clustering. Arthritis Rheum 2009; 61(10): 1328-36.
14. Grotle M, Hagen KB, Natvig B, Dahl FA, Kvien TK. Obesity and osteoarthritis in knee, hip and/or hand: an epidemiological study in the general population with 10 years follow-up. BMC Musculoskelet Disord 2008; 9: 132.
15. Stürmer T, Günther KP, Brenner H. Obesity, overweight and patterns of osteoarthritis: the Ulm Osteoarthritis Study. J Clin Epidemiol 2000; 53(3): 307-13.
16. Lementowski PW, Zelicof SB. Obesity and osteoarthritis. Am J Orthop (Belle Mead NJ) 2008; 37(3): 148-51.
17. Gomez R, Lago F, Gomez-Reino J, Dieguez C, Gualillo O. Adipokines in the skeleton: influence on cartilage function and joint degenerative diseases. J Mol Endocrinol 2009; 43(1): 11-8.
18. Fuerst M, Bertrand J, Lammers L, et al. Calcification of articular cartilage in human osteoarthritis. Arthritis Rheum 2009; 60(9): 2694-703.
19. Richette P, Bardin T, Doherty M. An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease. Rheumatology (Oxford) 2009; 48(7): 711-5.
20. Derfus BA, Kurian JB, Butler JJ, et al. The high prevalence of pathologic calcium crystals in pre-operative knees. J Rheumatol 2002; 29(3): 570-4.
21. Felson DT, Goggins J, Niu J, Zhang Y, Hunter DJ. The effect of body weight on progression of knee osteoarthritis is dependent on alignment. Arthritis Rheum 2004; 50(12): 3904-9.
22. Niu J, Zhang YQ, Torner J, et al. Is obesity a risk factor for progressive radiographic knee osteoarthritis? Arthritis Rheum 2009; 61(3): 329-35.
23. Bulló M, García-Lorda P, Megias I, Salas-Salvadó J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res 2003; 11(4): 525-31.
24. Miller GD, Nicklas BJ, Loeser RF. Inflammatory biomarkers and physical function in older, obese adults with knee pain and selfreported osteoarthritis after intensive weight-loss therapy. J Am Geriatr Soc 2008; 56(4): 644-51.
25. Charni-Ben Tabassi N, Garnero P. Monitoring cartilage turnover. Curr Rheumatol Rep 2007; 9(1): 16-24.
26. Garnero P. Use of biochemical markers to study and follow patients with osteoarthritis. Curr Rheumatol Rep 2006; 8(1): 37-44.
27. Huang K, Wu LD. Aggrecanase and aggrecan degradation in osteoarthritis: a review. J Int Med Res 2008; 36(6): 1149-60.
28. Malemud CJ. Anticytokine therapy for osteoarthritis: evidence to date. Drugs Aging 2010; 27(2): 95-115.
29. Sofat N. Analysing the role of endogenous matrix molecules in the development of osteoarthritis. Int J Exp Pathol 2009; 90(5): 463-79.
30. Aigner T, Söder S, Gebhard PM, McAlinden A, Haag J. Mechanisms of disease: role of chondrocytes in the pathogenesis of osteoarthritis-structure, chaos and senescence. Nat Clin Pract Rheumatol 2007; 3(7): 391-9.
31. Echtermeyer F, Bertrand J, Dreier R, et al. Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis. Nat Med 2009; 15(9): 1072-6.
32. Huang K, Wu LD. Suppression of aggrecanase: a novel protective mechanism of dehydroepiandrosterone in osteoarthritis? Mol Biol Rep 2010; 37(3): 1241-5.
33. Bondeson J, Wainwright S, Hughes C, Caterson B. The regulation of the ADAMTS4 and ADAMTS5 aggrecanases in osteoarthritis: a review. Clin Exp Rheumatol 2008; 26(1): 139-45.
34. Glasson SS, Askew R, Sheppard B, et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005; 434(7033): 644-8.
35. Sandy JD, Verscharen C. Analysis of aggrecan in human knee cartilage and synovial fluid indicates that aggrecanase (ADAMTS) activity is responsible for the catabolic turnover and loss of whole aggrecan whereas other protease activity is required for C-terminal processing in vivo. Biochem J 2001; 358(Pt 3): 615-26.
36. Yasumoto T, Bird JL, Sugimoto K, Mason RM, Bayliss MT. The G1 domain of aggrecan released from porcine articular cartilage forms stable complexes with hyaluronan/link protein. Rheumatology (Oxford) 2003; 42(2): 336-42.
37. Tortorella MD, Malfait AM, Deccico C, Arner E. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cartilage 2001; 9(6): 539-52.
38. Pratta MA, Scherle PA, Yang G, Liu RQ, Newton RC. Induction of aggrecanase 1 (ADAM-TS4) by interleukin-1 occurs through activation of constitutively produced protein. Arthritis Rheum 2003; 48(1): 119-33.
39. Yamanishi Y, Boyle DL, Clark M, et al. Expression and regulation of aggrecanase in arthritis: the role of TGF-beta. J Immunol 2002; 168(3): 1405-12.
40. Kashiwagi M, Tortorella M, Nagase H, Brew K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem 2001; 276(16): 12501-4.
41. Wayne GJ, Deng SJ, Amour A, et al. TIMP-3 inhibition of ADAMTS-4 (Aggrecanase-1) is modulated by interactions between aggrecan and the C-terminal domain of ADAMTS-4. J Biol Chem 2007; 282(29): 20991-8.
42. Hashimoto G, Aoki T, Nakamura H, Tanzawa K, Okada Y. Inhibition of ADAMTS4 (aggrecanase-1) by tissue inhibitors of metalloproteinases (TIMP-1, 2, 3 and 4). FEBS Lett 2001; 494(3): 192-5.
43. Wheeler CA, Jafarzadeh SR, Rocke DM, Grodzinsky AJ. IGF-1 does not moderate the time-dependent transcriptional patterns of key homeostatic genes induced by sustained compression of bovine cartilage. Osteoarthritis Cartilage 2009; 17(7): 944-52.
44. Xiang Y, Masuko-Hongo K, Sekine T, et al. Expression of proteinase-activated receptors (PAR)-2 in articular chondrocytes is modulated by IL-1beta, TNF-alpha and TGF-beta. Osteoarthritis Cartilage 2006; 14(11): 1163-73.
45. Boileau C, Amiable N, Martel-Pelletier J, Fahmi H, Duval N, Pelletier JP. Activation of proteinase-activated receptor 2 in human osteoarthritic cartilage upregulates catabolic and proinflammatory pathways capable of inducing cartilage degradation: a basic science study. Arthritis Res Ther 2007; 9(6): R121.
46. Tsai SH, Sheu MT, Liang YC, Cheng HT, Fang SS, Chen CH. TGF-beta inhibits IL-1beta-activated PAR-2 expression through multiple pathways in human primary synovial cells. J Biomed Sci 2009; 16: 97.
47. Martel-Pelletier J, Faure MP, McCollum R, Mineau F, Cloutier JM, Pelletier JP. Plasmin, plasminogen activators and inhibitor in human osteoarthritic cartilage. J Rheumatol 1991; 18(12): 1863-71.
48. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. Proteinase-activated receptors. Pharmacol Rev 2001; 53(2): 245-82.
49. Hollenberg MD, Compton SJ. International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol Rev 2002; 54(2): 203-17.
50. Sutton S, Clutterbuck A, Harris P, et al. The contribution of the synovium, synovial derived inflammatory cytokines and neuropeptides to the pathogenesis of osteoarthritis. Vet J 2009; 179(1): 10-24.
51. Jones AC, Chuck AJ, Arie EA, Green DJ, Doherty M. Diseases associated with calcium pyrophosphate deposition disease. Semin Arthritis Rheum 1992; 22(3): 188-202.
52. Harmey D, Hessle L, Narisawa S, Johnson KA, Terkeltaub R, Millán JL. Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol 2004; 164(4): 1199-209.
53. Harmey D, Johnson KA, Zelken J, et al. Elevated skeletal osteopontin levels contribute to the hypophosphatasia phenotype in Akp2(-/-) mice. J Bone Miner Res 2006; 21(9): 1377-86.
54. Nürnberg P, Thiele H, Chandler D, et al. Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia. Nat Genet 2001; 28(1): 37-41.
55. Ho AM, Johnson MD, Kingsley DM. Role of the mouse ank gene in control of tissue calcification and arthritis. Science 2000; 289(5477): 265-70.
56. Pendleton A, Johnson MD, Hughes A, et al. Mutations in ANKH cause chondrocalcinosis. Am J Hum Genet 2002; 71(4): 933-40.
57. Hessle L, Johnson KA, Anderson HC, et al. Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci U S A 2002; 99(14): 9445-9.
58. Suk EK, Malkin I, Dahm S, et al. Association of ENPP1 gene polymorphisms with hand osteoarthritis in a Chuvasha population. Arthritis Res Ther 2005; 7(5): R1082-90.
59. Wang J, Tsui HW, Beier F, Pritzker KP, Inman RD, Tsui FW. The ANKH DeltaE490Mutation in Calcium Pyrophosphate Dihydrate Crystal Deposition Disease (CPPDD) Affects Tissue Non-specific Alkaline Phosphatase (TNAP) Activities. Open Rheumatol J 2008; 2: 23-30.
60. Rosenthal AK. Update in calcium deposition diseases. Curr Opin Rheumatol 2007; 19(2): 158-62.
61. Cecil DL, Rose DM, Terkeltaub R, Liu-Bryan R. Role of interleukin-8 in PiT-1 expression and CXCR1-mediated inorganic phosphate uptake in chondrocytes. Arthritis Rheum 2005; 52(1): 144-54.
62. Fukui N, Ikeda Y, Ohnuki T, et al. Pro-inflammatory cytokine tumor necrosis factor-alpha induces bone morphogenetic protein-2 in chondrocytes via mRNA stabilization and transcriptional upregulation. J Biol Chem 2006; 281(37): 27229-41.
63. Livshits G. Quantitative genetics of circulating molecules associated with bone metabolism: a review. J Musculoskelet Neuronal Interact 2006; 6(1): 47-61.
64. Lories RJ, Luyten FP. Bone morphogenetic protein signaling and arthritis. Cytokine Growth Factor Rev 2009; 20(5-6): 467-73.
65. Hurtig M, Chubinskaya S, Dickey J, Rueger D. BMP-7 protects against progression of cartilage degeneration after impact injury. J Orthop Res 2009; 27(5): 602-11.
66. Miyamoto Y, Mabuchi A, Shi D, et al. A functional polymorphism in the 5' UTR of GDF5 is associated with susceptibility to osteoarthritis. Nat Genet 2007; 39(4): 529-33.
67. Fahey M, Mitton E, Muth E, Rosenthal AK. Dexamethasone promotes calcium pyrophosphate dihydrate crystal formation by articular chondrocytes. J Rheumatol 2009; 36(1): 163-9.
68. Orlandi A, Oliva F, Taurisano G, et al. Transglutaminase-2 differently regulates cartilage destruction and osteophyte formation in a surgical model of osteoarthritis. Amino Acids 2009; 36(4): 755-63.
69. Ding C, Parameswaran V, Cicuttini F, et al. Association between leptin, body composition, sex and knee cartilage morphology in older adults: the Tasmanian older adult cohort (TASOAC) study. Ann Rheum Dis 2008; 67(9): 1256-61.
70. Gandhi R, Takahashi M, Syed K, Davey JR, Mahomed NN. Relationship between body habitus and joint leptin levels in a knee osteoarthritis population. J Orthop Res 2010; 28(3): 329-33.
71. Thomas T. The complex effects of leptin on bone metabolism through multiple pathways. Curr Opin Pharmacol 2004; 4(3): 295-300.
72. Reseland JE, Syversen U, Bakke I, et al. Leptin is expressed in and secreted from primary cultures of human osteoblasts and promotes bone mineralization. J Bone Miner Res 2001; 16(8): 1426-33.
73. Simopoulou T, Malizos KN, Iliopoulos D, et al. Differential expression of leptin and leptin's receptor isoform (Ob-Rb) mRNA between advanced and minimally affected osteoarthritic cartilage; effect on cartilage metabolism. Osteoarthritis Cartilage 2007; 15(8): 872-83.
74. Bao JP, Chen WP, Feng J, Hu PF, Shi ZL, Wu LD. Leptin plays a catabolic role on articular cartilage. Mol Biol Rep 2009. [Epub ahead of print].
75. Dumond H, Presle N, Terlain B, et al. Evidence for a key role of leptin in osteoarthritis. Arthritis Rheum 2003; 48(11): 3118-29.
76. Bini V, Igli BG, Papi F, Celi F, Saggese G, Falorni A. Relationships of serum leptin levels with biochemical markers of bone turnover and with growth factors in normal weight and overweight children. Horm Res 2004; 61(4): 170-5.
77. Iliopoulos D, Malizos KN, Tsezou A. Epigenetic regulation of leptin affects MMP-13 expression in osteoarthritic chondrocytes: possible molecular target for osteoarthritis therapeutic intervention. Ann Rheum Dis 2007; 66(12): 1616-21.
78. Gandhi R, Takahashi M, Smith H, Rizek R, Mahomed NN. The synovial fluid adiponectin-leptin ratio predicts pain with knee osteoarthritis. Clin Rheumatol 2010 [Epub ahead of print].
79. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270(45): 26746-9.
80. Shapiro L, Scherer PE. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 1998; 8(6): 335-8.
81. Gabay O, Berenbaum F. Adipokines in arthritis: New Kids on the block. Curr Rheumatol Rev 2009; 5: 226-32.
82. Schäffler A, Ehling A, Neumann E, et al. Adipocytokines in synovial fluid. JAMA 2003; 290(13): 1709-10.
83. Ehling A, Schäffler A, Herfarth H, et al. The potential of adiponectin in driving arthritis. J Immunol 2006; 176(7): 4468-78.
84. Ushiyama T, Chano T, Inoue K, Matsusue Y. Cytokine production in the infrapatellar fat pad: another source of cytokines in knee synovial fluids. Ann Rheum Dis 2003; 62(2): 108-12.
85. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257(1): 79-83.
86. Oh DK, Ciaraldi T, Henry RR. Adiponectin in health and disease. Diabetes Obes Metab 2007; 9(3): 282-9.
87. Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50(9): 2094-9.
88. Pantsulaia Ia, Trofimova S, Kobyliansky E, Livshits G. Relationship between obesity, adipocytokines, and blood pressure: possible common genetic and environmental factors. Am J Hum Biol 2009; 21(1): 84-90.
89. Koenen TB, van Tits LJ, Holewijn S, et al. Adiponectin multimer distribution in patients with familial combined hyperlipidemia. Biochem Biophys Res Commun 2008; 376(1): 164-8.
90. Engl J, Bobbert T, Ciardi C, et al. Effects of pronounced weight loss on adiponectin oligomer composition and metabolic parameters. Obesity (Silver Spring) 2007; 15(5): 1172-8.
91. Haugen F, Drevon CA. Activation of nuclear factor-kappaB by high molecular weight and globular adiponectin. Endocrinology 2007; 148(11): 5478-86.
92. Kwan TS, Pelletier JP, Lajeunesse D, Fahmi H, Lavigne M, Martel-Pelletier J. The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells. Clin Exp Rheumatol 2008; 26(2): 295-304.
93. Matsuzawa Y. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 2006; 3(1): 35-42.
94. Chen TH, Chen L, Hsieh MS, Chang CP, Chou DT, Tsai SH. Evidence for a protective role for adiponectin in osteoarthritis. Biochim Biophys Acta 2006; 1762(8): 711-8.
95. Fasshauer M, Kralisch S, Klier M, et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2003; 301(4): 1045-50.
96. Filková M, Lisková M, Hulejová H, et al. Increased serum adiponectin levels in female patients with erosive compared with non-erosive osteoarthritis. Ann Rheum Dis 2009; 68(2): 295-6.
97. Distel E, Cadoudal T, Durant S, Poignard A, Chevalier X, Benelli C. The infrapatellar fat pad in knee osteoarthritis: an important source of interleukin-6 and its soluble receptor. Arthritis Rheum 2009; 60(11): 3374-7.
98. Ding C, Stannus O, Cicuttini F, Dore D, Jones G. The associations between leptin, interleukin 6 and hip radiographic osteoarthritis in older people. Osteoarthritis Cartilage 2009; 17(Suppl 1): S16-S17.
99. Lago F, Dieguez C, Gómez-Reino J, Gualillo O. Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol 2007; 3(12): 716-24.
100. Botter SM, Glasson SS, Hopkins B, et al. ADAMTS5-/-mice have less subchondral bone changes after induction of osteoarthritis through surgical instability: implications for a link between cartilage and subchondral bone changes. Osteoarthritis Cartilage 2009; 17(5): 636-45.
101. Arkill KP, Winlove CP. Solute transport in the deep and calcified zones of articular cartilage. Osteoarthritis Cartilage 2008; 16(6): 708-14.
102. Burr DB. Increased biological activity of subchondral mineralized tissues underlies the progressive deterioration of articular cartilage in osteoarthritis. J Rheumatol 2005; 32(6): 1156-8.
103. Couchourel D, Aubry I, Delalandre A, et al. Altered mineralization of human osteoarthritic osteoblasts is attributable to abnormal type I collagen production. Arthritis Rheum 2009; 60(5): 1438-50.
104. Berry PA, Maciewicz RA, Cicuttini FM, Jones MD, Hellawell CJ, Wluka AE. Markers of bone formation and resorption identify subgroups of patients with clinical knee osteoarthritis who have reduced rates of cartilage loss. J Rheumatol 2010 [Epub ahead of print].
105. van Spil WE, DeGroot J, Lems WF, Oostveen JC, Lafeber FP. Serum and urinary biochemical markers for knee and hiposteoarthritis: a systematic review applying the consensus BIPED criteria. Osteoarthritis Cartilage 2010; 18(5): 605-12.
106. Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008; 29(2): 155-92.
107. Tat SK, Pelletier JP, Velasco CR, Padrines M, Martel-Pelletier J. New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target? Keio J Med 2009; 58(1): 29-40.
108. Kwan TS, Amiable N, Pelletier JP, et al. Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis. Rheumatology (Oxford) 2009; 48(12): 1482-90.
109. Moreno-Rubio J, Herrero-Beaumont G, Tardio L, Alvarez-Soria MA, Largo R. Nonsteroidal antiinflammatory drugs and prostaglandin E(2) modulate the synthesis of osteoprotegerin and RANKL in the cartilage of patients with severe knee osteoarthritis. Arthritis Rheum 2010; 62(2): 478-88.
110. Ding C, Cicuttini F, Parameswaran V, Burgess J, Quinn S, Jones G. Serum levels of vitamin D, sunlight exposure, and knee cartilage loss in older adults: the Tasmanian older adult cohort study. Arthritis Rheum 2009; 60(5): 1381-9.
111. Bergink AP, Uitterlinden AG, Van Leeuwen JP, et al. Vitamin D status, bone mineral density, and the development of radiographic osteoarthritis of the knee: The Rotterdam Study. J Clin Rheumatol 2009; 15(5): 230-7.
112. Chaganti RK, Parimi N, Cawthon P, Dam TL, Nevitt MC, Lane NE. Association of 25-hydroxyvitamin D with prevalent osteoarthritis of the hip in elderly men: the osteoporotic fractures in men study. Arthritis Rheum 2010; 62(2): 511-4.
113. Felson DT, Niu J, Clancy M, et al. Low levels of vitamin D and worsening of knee osteoarthritis: results of two longitudinal studies. Arthritis Rheum 2007; 56(1): 129-36.
114. Ayral X, Pickering EH, Woodworth TG, Mackillop N, Dougados M. Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis - results of a 1 year longitudinal arthroscopic study in 422 patients. Osteoarthritis Cartilage 2005; 13(5): 361-7.
115. Jang D, Murrell GA. Nitric oxide in arthritis. Free Radic Biol Med 1998; 24(9): 1511-9.
116. McCarthy GM, Cheung HS. Point: Hydroxyapatite crystal deposition is intimately involved in the pathogenesis and progression of human osteoarthritis. Curr Rheumatol Rep 2009; 11(2): 141-7.
117. Spinella DG. Biomarkers in clinical drug development: realizing the promise. Biomark Med 2009; 3(6): 667-9.
118. Rousseau JC, Delmas PD. Biological markers in osteoarthritis. Nat Clin Pract Rheumatol 2007; 3(6): 346-56.
119. Williams FM, Spector TD. Biomarkers in osteoarthritis. Arthritis Res Ther 2008; 10(1): 101.
120. Elsaid KA, Chichester CO. Review: Collagen markers in early arthritic diseases. Clin Chim Acta 2006; 365(1-2): 68-77.
121. Qvist P, Christiansen C, Karsdal MA, Madsen SH, Sondergaard BC, Bay-Jensen AC. Application of biochemical markers in development of drugs for treatment of osteoarthritis. Biomarkers 2010; 15(1): 1-19.
122. Bauer DC, Hunter DJ, Abramson SB, et al; Osteoarthritis Biomarkers Network. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 2006; 14(8): 723-7.
123. Nielsen RH, Stoop R, Leeming DJ, et al. Evaluation of cartilage damage by measuring collagen degradation products in joint extracts in a traumatic model of osteoarthritis. Biomarkers 2008; 13(1): 79-87.
124. Dam EB, Byrjalsen I, Karsdal MA, Qvist P, Christiansen C. Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI. Osteoarthritis Cartilage 2009; 17(3): 384-9.
125. Henrotin Y, Addison S, Kraus V, Deberg M. Type II collagen markers in osteoarthritis: what do they indicate? Curr Opin Rheumatol 2007; 19(5): 444-50.
126. Charni N, Juillet F, Garnero P. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 2005; 52(4): 1081-90.
127. Christgau S, Garnero P, Fledelius C, et al. Collagen type II Ctelopeptide fragments as an index of cartilage degradation. Bone 2001; 29(3): 209-15.
128. Rousseau JC, Zhu Y, Miossec P, et al. Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2004; 12(6): 440-7.
129. Garnero P, Conrozier T, Christgau S, Mathieu P, Delmas PD, Vignon E. Urinary type II collagen C-telopeptide levels are increased in patients with rapidly destructive hip osteoarthritis. Ann Rheum Dis 2003; 62(10): 939-43.
130. Meulenbelt I, Kloppenburg M, Kroon HM, et al. Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: the GARP study. Ann Rheum Dis 2006; 65(3): 360-5.
131. Conrozier T, Ferrand F, Poole AR, et al. Differences in biomarkers of type II collagen in atrophic and hypertrophic osteoarthritis of the hip: implications for the differing pathobiologies. Osteoarthritis Cartilage 2007; 15(4): 462-7.
132. Conrozier T, Poole AR, Ferrand F, et al. Serum concentrations of type II collagen biomarkers (C2C, C1, 2C and CPII) suggest different pathophysiologies in patients with hip osteoarthritis. Clin Exp Rheumatol 2008; 26(3): 430-5.
133. Nelson F, Dahlberg L, Laverty S, et al. Evidence for altered synthesis of type II collagen in patients with osteoarthritis. J Clin Invest 1998; 102(12): 2115-25.
134. Ishiguro N, Ito T, Ito H, et al. Relationship of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover: analyses of synovial fluid from patients with osteoarthritis. Arthritis Rheum 1999; 42(1): 129-36.
135. Shinmei M, Ito K, Matsuyama S, Yoshihara Y, Matsuzawa K. Joint fluid carboxy-terminal type II procollagen peptide as a marker of cartilage collagen biosynthesis. Osteoarthritis Cartilage 1993; 1(2): 121-8.
136. Hasegawa M, Nakoshi Y, Tsujii M, et al. Changes in biochemical markers and prediction of effectiveness of intra-articular hyaluronan in patients with knee osteoarthritis. Osteoarthritis Cartilage 2008; 16(4): 526-9.
137. Jansen NW, Roosendaal G, Lundin B, et al. The combination of the biomarkers urinary C-terminal telopeptide of type II collagen, serum cartilage oligomeric matrix protein, and serum chondroitin sulfate 846 reflects cartilage damage in hemophilic arthropathy. Arthritis Rheum 2009; 60(1): 290-8.
138. Aigner T, Zhu Y, Chansky HH, Matsen FA 3rd, Maloney WJ, Sandell LJ. Reexpression of type IIA procollagen by adult articular chondrocytes in osteoarthritic cartilage. Arthritis Rheum 1999; 42(7): 1443-50.
139. Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis 2001; 60(6): 619-26.
140. Punzi L, Oliviero F, Plebani M. New biochemical insights into the pathogenesis of osteoarthritis and the role of laboratory investigations in clinical assessment. Crit Rev Clin Lab Sci 2005; 42(4): 279-309.
141. Rizkalla G, Reiner A, Bogoch E, Poole AR. Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease. J Clin Invest 1992; 90(6): 2268-77.
142. Clark AG, Jordan JM, Vilim V, et al. Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. Arthritis Rheum 1999; 42(11): 2356-64.
143. Tseng S, Reddi AH, Di Cesare PE. Cartilage Oligomeric Matrix Protein (COMP): A biomarker of arthritis. Biomark Insights 2009; 4: 33-44.
144. Hunter DJ, Li J, LaValley M, et al. Cartilage markers and their association with cartilage loss on magnetic resonance imaging in knee osteoarthritis: the Boston Osteoarthritis Knee Study. Arthritis Res Ther 2007; 9(5): R108.
145. Conrozier T, Saxne T, Fan CS, et al. Serum concentrations of cartilage oligomeric matrix protein and bone sialoprotein in hip osteoarthritis: a one year prospective study. Ann Rheum Dis 1998; 57(9): 527-32.
146. Date H, Yamada H, Morita M, et al. Serum cartilage oligomeric matrix protein and hyaluronan levels are useful in the evaluation of knee osteoarthritis and the prediction of disease progression in the following 2 years. Osteoarthritis Cartilage 2010; 16(Suppl 4): S50.
147. Vilím V, Vytásek R, Olejárová M, et al. Serum cartilage oligomeric matrix protein reflects the presence of clinically diagnosed synovitis in patients with knee osteoarthritis. Osteoarthritis Cartilage 2001; 9(7): 612-8.
148. Huang K, Wu LD. YKL-40: a potential biomarker for osteoarthritis. J Int Med Res 2009; 37(1): 18-24.
149. Zivanović S, Rackov LP, Vojvodić D, Vucetić D. Human cartilage glycoprotein 39-biomarker of joint damage in knee osteoarthritis. Int Orthop 2009; 33(4): 1165-70.
150. Johansen JS, Hvolris J, Hansen M, Backer V, Lorenzen I, Price PA. Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br J Rheumatol 1996; 35(6): 553-9.
151. Bierma-Zeinstra SM, Koes BW. Risk factors and prognostic factors of hip and knee osteoarthritis. Nat Clin Pract Rheumatol 2007; 3(2): 78-85.
152. Anitua E, Sánchez M, de la Fuente M, et al. Relationship between investigative biomarkers and radiographic grading in patients with knee osteoarthritis. Int J Rheumatol 2009; 2009: 1-4.
153. Elliott AL, Kraus VB, Luta G, et al. Serum hyaluronan levels and radiographic knee and hip osteoarthritis in African Americans and Caucasians in the Johnston County Osteoarthritis Project. Arthritis Rheum 2005; 52(1): 105-11.
154. Pavelka K, Forejtová S, Olejárová M, et al. Hyaluronic acid levels may have predictive value for the progression of knee osteoarthritis. Osteoarthritis Cartilage 2004; 12(4): 277-83.
155. Verzijl N, Bank RA, TeKoppele JM, DeGroot J. AGEing and osteoarthritis: a different perspective. Curr Opin Rheumatol 2003; 15(5): 616-22.
156. Jordan KM, Syddall HE, Garnero P, et al. Urinary CTX-II and glucosyl-galactosyl-pyridinoline are associated with the presence and severity of radiographic knee osteoarthritis in men. Ann Rheum Dis 2006; 65(7): 871-7.
157. Filková M, Senolt L, Braun M, et al. Serum hyaluronic acid as a potential marker with a predictive value for further radiographic progression of hand osteoarthritis. Osteoarthritis Cartilage 2009; 17(12): 1615-9.
158. Lohmander LS, Brandt KD, Mazzuca SA, et al. Use of the plasma stromelysin (matrix metalloproteinase 3) concentration to predict joint space narrowing in knee osteoarthritis. Arthritis Rheum 2005; 52(10): 3160-7.
159. Malaval L, Wade-Guéye NM, Boudiffa M, et al. Bone sialoprotein plays a functional role in bone formation and osteoclastogenesis. J Exp Med 2008; 205(5): 1145-53.
160. Petersson IF, Boegård T, Svensson B, Heinegård D, Saxne T. Changes in cartilage and bone metabolism identified by serum markers in early osteoarthritis of the knee joint. Br J Rheumatol 1998; 37(1): 46-50.
161. Birmingham JD, Vilim V, Kraus VB. Collagen biomarkers for arthritis applications. Biomark Insights 2007; 1: 61-76.
162. Kraus VB, Nevitt M, Sandell LJ. Summary of the OA biomarkers workshop 2009 - biochemical biomarkers: biology, validation, and clinical studies. Osteoarthritis Cartilage 2010; [Epub ahead of print].